Ann Transplant 2008; 13(1): 25-25 :: ID: 880179
The purpose of this work is to summarize the current trends in tacrolimus (TAC) optimisation in transplant patients. Knowledge of the analytical method used to monitor TAC is mandatory (cross-reactivity, interferences, calibration bias, reproducibility, sensitivity, ...). Even more important is the ability to draw comparison among the different methods available (patients outcome according to TAC blood levels, multicenter clinical trials, ...). The choice of the analytical method should depend upon each laboratory characteristics (number of samples, staff experience, equipment, ...), and on the experience of clinicians with a particular method. Even though the vast majority of laboratories use immunoassays, implementation of LC-MS(MS) is increasing (2% in 1999, 19% in 2007). A large discussion exists about the most accurate approach to evaluate drug exposure or AUC (single time point -C0 or others-, limited sampling strategy or Bayesian estimates, ...). Most multi-centre trials (e.g. SYMPHONY study) stress the importance of concomitant therapies, time post-transplantation and transplant type, in defining appropriate TAC target concentrations. Recent data suggest a reduction in the recommended target TAC concentration down to 3-7 ng/mL when the drug is associated to daclizumab, MMF and steroids. Treatment management should also most likely take advantage of integrating the genetic polymorphism of proteins or enzymes involved in the tacrolimus drug disposition, in order to reach earlier optimal dosage regimen. TAC blood concentrations clearly correlate with the risk of side effects, whereas the relationship with efficacy seems much weaker. Research protocols are currently ongoing precisely to improve the predictability of the treatment efficacy (pharmacodynamic markers, drug concentration within target tissue, ...).
Keywords: cross-reactivity, biothecnology, proteomes
06 May 2022 : Original articlePhosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...
Ann Transplant In Press; DOI: 10.12659/AOT.936293
Most Viewed Current Articles
31 Dec 1969 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588
31 Dec 1969 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
31 Dec 1969 : Review articleKidney Transplantation in the Times of COVID-19 – A Literature Review
Ann Transplant 2020; 25:e925755